FDA AdCom Continues to Discuss Ardelyx's (ARDX) Discuss XPHOZAH

Ardelyx, Inc. (Nasdaq: ARDX) today announced that Nasdaq has halted trading of the Company's common stock.

The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) is meeting to discuss the company's New Drug Application (NDA) for XPHOZAH (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

The Advisory Committee meeting is scheduled for Wednesday, November 16, from 9:30 am to 5:00 pm ET. The briefing materials can be found on the FDA website at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-16-2022-meeting-cardiovascular-and-renal-drugs-advisory-committee-meeting-announcement#event-materials.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
• FDA set to permanently fill top drug, vaccine, and tobacco roles - Bloomberg
• Satellos drug candidate SAT-3247 receives WHO nonproprietary name